Patents by Inventor Paul G. Tardi

Paul G. Tardi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Sphingosomes for enhanced drug delivery
    Patent number: 5814335
    Abstract: Liposomal formulations having extended circulation time in vivo and increased drug retention are comprised of sphingomyelin and cholesterol and have an acidic intraliposomal pH. The formulations have enhanced stability and thus are used in methods which provide improved drug delivery and more effective treatment. The delivery of ciprofloxacin, and alkaloid drugs, particularly swainsonine, vincristine and vinblastine, is significantly improved.
    Type: Grant
    Filed: September 17, 1997
    Date of Patent: September 29, 1998
    Assignee: Inex Pharmaceuticals Corporation
    Inventors: Murray S. Webb, Marcel B. Bally, Lawrence D. Mayer, James J. Miller, Paul G. Tardi
  • Methods for increasing the circulation half-life of protein-based therapeutics
    Patent number: 5780054
    Abstract: Methods of increasing the circulation half-life of protein-based therapeutics in a host, the methods comprising: (a) administering to the host an amount of a first liposome formulation comprising liposomes and an antineoplastic agent; and (b) administering to the host a second formulation comprising the protein-based therapeutic, wherein the amount of the first liposome formulation is sufficient to suppress an immune response to the protein-based therapeutic of the second formulation, thereby increasing the circulation half-life of the protein-based therapeutic.
    Type: Grant
    Filed: January 17, 1996
    Date of Patent: July 14, 1998
    Assignee: University of British Columbia
    Inventors: Paul G. Tardi, Erik Swartz, Marcel B. Bally, Pieter R. Cullis
  • Sphingosomes for enhanced drug delivery
    Patent number: 5741516
    Abstract: Liposomal formulations having extended circulation time in vivo and increased drug retention are comprised of sphingomyelin and cholesterol and have an acidic intraliposomal pH. The formulations have enhanced stability and thus are used in methods which provide improved drug delivery and more effective treatment. The delivery of ciprofloxacin, and alkaloid drugs, particularly swainsonine, vincristine and vinblastine, is significantly improved.
    Type: Grant
    Filed: December 14, 1995
    Date of Patent: April 21, 1998
    Assignee: Inex Pharmaceuticals Corporation
    Inventors: Murray S. Webb, Marcel B. Bally, Lawrence D. Mayer, James J. Miller, Paul G. Tardi